{"name":"Kalbe Farma","slug":"kalbe","ticker":"KLBF.JK","exchange":"IDX","domain":"kalbe.co.id","description":"PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.\nThe Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.","hq":"Jakarta, Indonesia","founded":1966,"employees":"12895","ceo":"Vidjongtius","sector":"Generics / Consumer Health / Nutrition","stockPrice":850,"stockChange":-20,"stockChangePercent":-2.3,"marketCap":"$2.2B","metrics":{"revenue":2074153283.261175,"revenueGrowth":10.1,"grossMargin":38.3,"rdSpend":0,"netIncome":207167934.04897362,"cash":260395298.62871385,"dividendYield":4.24,"peRatio":10.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Vitamin C patent cliff ($10.5M at risk)","drug":"Vitamin C","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Multivitamin patent cliff ($20.8M at risk)","drug":"Multivitamin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-03-31","type":"earnings","headline":"Kalbe Farma Reports 2022 Annual Results","summary":"Kalbe Farma reported a 10% increase in revenue and a 15% increase in net income for the year 2022.","drugName":"","sentiment":"positive"},{"date":"2021-09-01","type":"deal","headline":"Kalbe Farma Partners with Local University for Research and Development","summary":"Kalbe Farma partnered with a local university to conduct research and development on new medicines and products.","drugName":"","sentiment":"neutral"}],"realNews":[],"patents":[{"drugName":"Vitamin C","drugSlug":"ascorbic-acid","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"Indonesia","annualRevenue":10500000},{"drugName":"Multivitamin","drugSlug":"multivitamin-complex","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"Indonesia","annualRevenue":20800000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Eva Pharma","Indofarma","Kimia Farma"],"therapeuticFocus":["Generics","Consumer Health","Nutrition"],"financials":{"source":"yahoo_finance","revenue":2023169808.4108799,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":2023169808.4108799},{"period":"2024-12-31","value":1868715738.23552},{"period":"2023-12-31","value":1743936701.8606555},{"period":"2022-12-31","value":1657130775.8825753}],"grossProfit":794417602.27187,"grossProfitHistory":[{"period":"2025-12-31","value":794417602.27187},{"period":"2024-12-31","value":730811357.89182},{"period":"2023-12-31","value":666409470.7122176},{"period":"2022-12-31","value":659813123.2963432}],"rdSpend":28620332.88047,"rdSpendHistory":[{"period":"2025-12-31","value":28620332.88047},{"period":"2024-12-31","value":27010309.932},{"period":"2023-12-31","value":18878639.621525154},{"period":"2022-12-31","value":16799532.703398623}],"sgaSpend":301303615.53897,"operatingIncome":260310258.30409,"operatingIncomeHistory":[{"period":"2025-12-31","value":260310258.30409},{"period":"2024-12-31","value":232957966.69142},{"period":"2023-12-31","value":207625264.4188039},{"period":"2022-12-31","value":241961882.29722998}],"netIncome":209908252.50246,"netIncomeHistory":[{"period":"2025-12-31","value":209908252.50246},{"period":"2024-12-31","value":185603498.19149},{"period":"2023-12-31","value":158462090.89406085},{"period":"2022-12-31","value":193711904.40231824}],"eps":80.51,"epsHistory":[{"period":"2025-12-31","value":80.51},{"period":"2024-12-31","value":70.16},{"period":"2023-12-31","value":59.81},{"period":"2022-12-31","value":72.71}],"cash":248077898.3288,"cashHistory":[{"period":"2025-12-31","value":248077898.3288},{"period":"2024-12-31","value":270520854.19838},{"period":"2023-12-31","value":185132913.80261046},{"period":"2022-12-31","value":226218152.95368877}],"totalAssets":1758267396.50196,"totalLiabilities":341972803.23565,"totalDebt":17026518.16691,"equity":1335192300.35289,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":-46384422.65744,"capexHistory":[{"period":"2025-12-31","value":-46384422.65744},{"period":"2024-12-31","value":-71611399.21294999},{"period":"2023-12-31","value":-67524183.4902135},{"period":"2022-12-31","value":-49833896.289943606}],"freeCashflow":140938319.56191,"dividendsPaid":-93688547.51354,"buybacks":-48229497.15799,"employees":12895,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":76523713.19207999,"ebit":77691067.17221999,"ebitda":82541640.02729,"period":"2026-03-31","revenue":554316221.89097,"epsBasic":22.74,"netIncome":58930528.34479,"rdExpense":6480068.88534,"epsDiluted":22.74,"grossProfit":209830990.18673,"operatingIncome":75474056.80928999},{"sga":64570041.6658023,"ebit":74863579.21565045,"ebitda":79349049.71240045,"period":"2025-12-31","revenue":534722087.8732066,"epsBasic":null,"netIncome":59201185.35191263,"rdExpense":8838109.703286603,"epsDiluted":null,"grossProfit":198547477.09413862,"operatingIncome":73327763.71210343},{"sga":92917811.77358235,"ebit":null,"ebitda":null,"period":"2025-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":198585040.64516222,"operatingIncome":null},{"sga":71888798.89652447,"ebit":68379684.19556724,"ebitda":74461863.17660476,"period":"2025-06-30","revenue":471587996.10819095,"epsBasic":null,"netIncome":51441329.07237154,"rdExpense":7844911.5558262365,"epsDiluted":null,"grossProfit":189436613.44891346,"operatingIncome":60171768.64349926},{"sga":68894732.48053999,"ebit":82397882.86459,"ebitda":86933621.80597,"period":"2025-03-31","revenue":503332772.7763,"epsBasic":23.57,"netIncome":61670849.144209996,"rdExpense":6118957.76549,"epsDiluted":23.57,"grossProfit":204573659.01712,"operatingIncome":78801662.84628999},{"sga":null,"ebit":65418195.84526234,"ebitda":70113339.95006466,"period":"2024-12-31","revenue":480470422.66839194,"epsBasic":null,"netIncome":49384739.42775671,"rdExpense":8825221.010592107,"epsDiluted":null,"grossProfit":null,"operatingIncome":61948920.053287536},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":850,"previousClose":870,"fiftyTwoWeekHigh":1600,"fiftyTwoWeekLow":850,"fiftyTwoWeekRange":"850.0 - 1600.0","fiftyDayAverage":952.2,"twoHundredDayAverage":1142.15,"beta":0.01,"enterpriseValue":2042271767.6177063,"forwardPE":11.4,"priceToBook":1.58,"priceToSales":1.06,"enterpriseToRevenue":0.98,"enterpriseToEbitda":6.74,"pegRatio":1.35,"ebitda":303031444.7931546,"ebitdaMargin":14.6,"freeCashflow":137231921.88779363,"operatingCashflow":182720963.5567842,"totalDebt":17502806.167439606,"debtToEquity":1.2,"currentRatio":3.56,"returnOnAssets":9,"returnOnEquity":14.4,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":16,"targetMeanPrice":1495,"targetHighPrice":1975,"targetLowPrice":1070,"dividendRate":36,"payoutRatio":0.45,"fiveYearAvgDividendYield":2.31,"exDividendDate":1748995200,"insiderHeldPercent":64.9,"institutionHeldPercent":11.4,"sharesOutstanding":45248860110,"floatShares":17993209223,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":79.65,"epsForward":74.81,"revenuePerShare":797.4,"bookValue":536.97,"officers":[{"age":63,"name":"Ms. Bernadette Ruth Irawati Setiady MSc.","title":"President Director"},{"age":58,"name":"Mr. Sie  Djohan","title":"Director of Corporate Business Development, Management System & Regulatory Affairs and Director"},{"age":55,"name":"Mr. Rustam  Tan","title":"Head of Internal Audit Unit"},{"age":53,"name":"Maria Teresa Fabiola","title":"Corporate Secretary"}],"industry":"Drug Manufacturers - General","irWebsite":"http://www.kalbefarma.com/?mn=investor&tipe=kalbe","website":"https://www.kalbe.co.id","phone":"62 21 4287 3888"}}